Top 5 Stocks to Buy Now
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel Free ZSQR Stock Alerts

Coeptis Therapeutics (ZSQR) Financials

Coeptis Therapeutics logo
$16.73 +1.14 (+7.31%)
As of 06/18/2026 04:00 PM Eastern
Compare
Annual Income Statements for Coeptis Therapeutics

Annual Income Statements for Coeptis Therapeutics

This table shows Coeptis Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.00 -17 -13 -38 -21 -11 -12
Consolidated Net Income / (Loss)		 -0.00 -17 -13 -38 -21 -11 -12
Net Income / (Loss) Continuing Operations		 -0.00 -17 -13 -38 -21 -11 -12
Total Pre-Tax Income 		-0.00 -17 -13 -38 -21 -11 -12
Total Operating Income		 -0.00 -0.07 -14 -34 -21 -10 -13
Total Gross Profit		 0.00 0.00 0.08 0.00 0.00 0.00 1.18
Total Revenue		 0.00 0.00 0.08 0.00 0.00 0.00 1.36
Operating Revenue		 - - 0.08 0.00 0.00 0.00 1.36
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.18
Operating Cost of Revenue		 - - 0.00 0.00 0.00 0.00 0.18
Total Operating Expenses		 0.00 0.07 14 34 21 10 14
Selling, General & Admin Expense		 0.00 0.07 14 34 12 3.90 8.94
Marketing Expense		 - - 0.00 0.01 - 0.00 0.11
Research & Development Expense		 - - 0.00 0.02 6.67 2.33 1.28
Amortization Expense		 - - - - - 1.00 1.00
Other Operating Expenses / (Income)		 - - - - 1.45 2.83 2.90
Total Other Income / (Expense), net		 0.00 -17 0.60 -3.38 0.22 -0.82 0.77
Interest Expense		 - - 0.19 3.61 0.11 0.46 0.64
Interest & Investment Income		 0.00 0.00 1.00 - - 0.23 -0.05
Other Income / (Expense), net		 0.00 -17 -0.22 0.23 0.33 -0.60 1.46
Income Tax Expense		 - - 0.00 0.00 0.00 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - 0.00 -0.20 -0.36
Basic Earnings per Share		 $0.00 ($5.63) - - ($16.56) ($5.56) ($2.81)
Weighted Average Basic Shares Outstanding		 0.00 1.19M 1.88M 20.44M 1.28M 1.92M 4.23M
Diluted Earnings per Share		 $0.00 - - - ($16.56) ($5.56) ($2.81)
Weighted Average Diluted Shares Outstanding		 0.00 1.88M 1.88M 20.44M 1.28M 1.92M 4.23M
Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.88M 1.88M 20.44M 36.09M 3.36M 6.22M

Quarterly Income Statements for Coeptis Therapeutics

This table shows Coeptis Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -6.35 -3.76 -3.00 -3.04 -3.66 -0.99 -3.49 -5.13 -5.80 5.86 -4.13
Consolidated Net Income / (Loss)		 -6.35 -3.76 -3.00 -3.04 -1.83 -3.01 -6.78 -4.33 -2.90 -1.62 -7.94
Net Income / (Loss) Continuing Operations		 -6.35 -3.76 -3.00 -3.04 -1.83 -3.01 -3.42 -3.53 -2.90 -2.42 -4.02
Total Pre-Tax Income 		-6.35 -3.76 -3.00 -3.04 -1.83 -3.01 -3.42 -4.33 -2.90 -1.62 -4.02
Total Operating Income		 -7.90 -3.37 -2.92 -2.83 -2.14 -2.16 -4.06 -4.52 -2.48 -1.99 -3.91
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.02 0.16 0.19 0.82 0.07
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.06 0.20 0.24 0.86 0.11
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.06 0.20 0.24 0.86 0.11
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.05 0.05 0.05 0.05 0.05
Operating Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.05 0.05 0.05 0.05 0.05
Total Operating Expenses		 7.90 3.37 2.92 2.83 2.14 2.16 4.07 4.68 2.67 2.81 3.98
Selling, General & Admin Expense		 2.07 1.43 1.35 1.10 0.60 0.83 2.59 3.50 1.26 1.58 1.66
Marketing Expense		 0.01 - 0.00 0.01 0.00 -0.01 0.11 0.00 0.00 -0.00 0.00
Research & Development Expense		 5.07 1.01 0.78 0.40 0.81 0.34 0.09 0.29 0.59 0.31 0.24
Amortization Expense		 - - - - 0.25 - 0.25 - 0.25 - 0.25
Other Operating Expenses / (Income)		 0.38 0.44 0.54 1.07 0.48 0.74 1.04 0.63 0.57 0.66 1.84
Total Other Income / (Expense), net		 1.55 -0.39 -0.08 -0.21 0.31 -0.85 0.64 0.19 -0.42 0.37 -0.11
Interest Expense		 0.02 0.01 0.20 0.07 0.05 0.14 0.07 0.07 0.06 0.44 0.01
Interest & Investment Income		 - - - - - - 0.00 - - - -0.02
Other Income / (Expense), net		 1.57 -0.38 0.12 -0.14 0.36 -0.94 0.71 0.25 -0.36 0.85 -0.08
Income Tax Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.00 - 0.00 0.00 0.10 -0.29 0.06 0.80 0.16 -1.68 0.10
Basic Earnings per Share		 ($0.24) ($2.92) ($0.08) - - ($0.51) ($1.10) - - $1.38 ($0.65)
Weighted Average Basic Shares Outstanding		 26.65M 1.28M 35.54M 39.72M 41.12M 1.92M 3.07M 4.82M 5.34M 4.23M 6.03M
Diluted Earnings per Share		 ($0.24) ($2.92) ($0.08) - - ($0.51) ($1.10) - - $1.38 ($0.65)
Weighted Average Diluted Shares Outstanding		 26.65M 1.28M 35.54M 39.72M 41.12M 1.92M 3.07M 4.82M 5.34M 4.23M 6.03M
Weighted Average Basic & Diluted Shares Outstanding		 34.11M 36.09M 37.12M 39.72M 41.12M 3.36M 3.51M 4.82M 5.34M 6.22M 51.43M

Annual Cash Flow Statements for Coeptis Therapeutics

This table details how cash moves in and out of Coeptis Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.00 0.91 1.98 1.61 -2.32 -0.94 5.14
Net Cash From Operating Activities		 -0.00 -0.12 -4.49 -3.88 -7.24 -6.65 -8.60
Net Cash From Continuing Operating Activities		 -0.00 -0.12 -4.49 -3.88 -7.24 -6.65 -8.60
Net Income / (Loss) Continuing Operations		 -0.00 -17 -13 -38 -21 -11 -12
Consolidated Net Income / (Loss)		 -0.00 -17 -13 -38 -21 -11 -12
Depreciation Expense		 - - 0.45 1.00 1.00 1.00 1.18
Amortization Expense		 - - - - 0.03 0.25 0.59
Non-Cash Adjustments To Reconcile Net Income		 0.00 17 11 33 11 2.25 4.22
Changes in Operating Assets and Liabilities, net		 0.00 -0.05 -2.98 -0.55 1.77 0.72 -2.32
Net Cash From Investing Activities		 0.00 -76 -1.75 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 -76 -1.75 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 0.00 77 8.22 5.49 4.92 5.71 14
Net Cash From Continuing Financing Activities		 0.00 77 8.22 5.49 4.92 5.71 14
Repayment of Debt		 0.00 -0.19 -1.70 -2.42 -1.23 -0.65 -0.22
Issuance of Debt		 0.09 0.04 0.08 0.00 0.65 1.85 0.99
Issuance of Preferred Equity		 - - - - - 3.91 5.46
Issuance of Common Equity		 0.00 77 10 3.27 5.49 0.60 4.56
Other Financing Activities, net		 - - -0.05 4.63 - 0.00 2.96
Cash Interest Paid		 - - 0.00 0.00 0.00 0.01 0.01
Cash Income Taxes Paid		 - - 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Coeptis Therapeutics

This table details how cash moves in and out of Coeptis Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.83 0.06 -0.44 0.53 -0.42 -0.60 3.74 -2.27 2.91 0.77 -0.46
Net Cash From Operating Activities		 -1.96 -1.69 -1.90 -1.42 -1.89 -1.44 -2.37 -2.40 -2.15 -1.69 -1.76
Net Cash From Continuing Operating Activities		 -1.96 -1.69 -1.90 -1.42 -1.89 -1.44 -2.37 -2.40 -2.15 -1.69 -1.76
Net Income / (Loss) Continuing Operations		 -6.35 -3.76 -3.00 -3.04 -1.83 -3.01 -3.42 -4.33 -2.90 -1.62 -4.02
Consolidated Net Income / (Loss)		 -6.35 -3.76 -3.00 -3.04 -1.83 -3.01 -3.42 -4.33 -2.90 -1.62 -4.02
Depreciation Expense		 0.25 0.25 0.25 0.25 0.25 0.25 0.30 0.30 0.30 0.30 0.30
Amortization Expense		 0.03 0.00 0.16 -0.01 0.03 0.08 0.11 0.40 0.07 0.01 0.02
Non-Cash Adjustments To Reconcile Net Income		 3.84 0.90 0.54 1.31 -0.23 0.62 1.18 3.03 0.81 -0.50 1.45
Changes in Operating Assets and Liabilities, net		 0.27 0.91 0.15 0.06 -0.11 0.63 -0.53 -1.79 -0.43 0.12 0.50
Net Cash From Investing Activities		 0.35 - -0.10 - - 0.10 0.00 - - - 0.59
Net Cash From Continuing Investing Activities		 0.35 - -0.10 - - 0.10 0.00 - - - 0.59
Sale and/or Maturity of Investments		 - - - - - - 0.00 - - - 0.59
Net Cash From Financing Activities		 -0.22 1.75 1.56 1.94 1.47 0.73 6.10 0.13 5.06 2.45 0.70
Net Cash From Continuing Financing Activities		 -0.22 1.75 1.56 1.94 1.47 0.73 6.10 0.13 5.06 2.45 0.70
Repayment of Debt		 -3.92 -0.35 -0.29 -0.30 - -0.06 -0.22 - - - 0.00
Issuance of Debt		 0.15 0.15 1.35 0.50 - - 0.99 - - - 0.00
Issuance of Preferred Equity		 - - 0.00 1.69 1.52 0.70 5.33 0.13 - - 0.00
Issuance of Common Equity		 3.54 1.95 0.50 0.05 -0.05 0.10 0.00 0.00 3.02 1.53 0.00
Other Financing Activities, net		 - - - - - - 0.00 - - 0.92 0.70
Cash Interest Paid		 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 - - 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for Coeptis Therapeutics

This table presents Coeptis Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.17 77 6.77 7.92 4.57 8.91 16
Total Current Assets		 0.00 0.96 2.18 3.94 1.75 1.05 7.35
Cash & Equivalents		 0.00 0.91 2.18 3.79 1.47 0.53 5.67
Short-Term Investments		 - - - - - 0.00 0.68
Note & Lease Receivable		 - - - 0.00 0.04 0.00 0.01
Prepaid Expenses		 0.00 0.05 0.00 0.14 0.24 0.52 0.99
Plant, Property, & Equipment, net		 0.00 0.00 0.01 0.01 0.01 0.01 0.01
Total Noncurrent Assets		 0.17 76 4.57 3.96 2.81 7.85 8.79
Intangible Assets		 - - - - 0.00 0.54 0.36
Other Noncurrent Operating Assets		 0.17 - 4.57 3.96 2.81 7.31 8.43
Total Liabilities & Shareholders' Equity		 0.17 77 6.77 7.92 4.57 8.91 16
Total Liabilities		 0.16 23 4.41 3.46 3.76 5.04 2.09
Total Current Liabilities		 0.16 0.01 2.76 2.17 2.99 4.51 1.77
Short-Term Debt		 0.15 - 2.42 1.85 0.98 1.19 0.10
Accounts Payable		 0.00 0.01 0.13 0.10 1.42 1.27 0.89
Accrued Expenses		 0.00 - 0.20 0.18 0.56 0.74 0.04
Current Deferred Revenue		 - - - - - 0.00 0.60
Other Current Liabilities		 - - 0.01 0.04 0.04 1.32 0.14
Total Noncurrent Liabilities		 0.00 23 1.65 1.29 0.77 0.53 0.32
Long-Term Debt		 - - 1.65 0.15 0.15 0.15 0.15
Other Noncurrent Operating Liabilities		 0.00 23 0.00 1.14 0.62 0.38 0.17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.02 -22 2.35 4.45 0.81 3.87 14
Total Preferred & Common Equity		 0.02 -22 2.35 4.45 0.81 3.38 14
Preferred Stock		 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Common Equity		 0.02 -22 2.35 4.45 0.81 3.38 14
Common Stock		 0.03 0.03 30 71 92 103 127
Retained Earnings		 -0.01 -22 -28 -66 -87 -98 -110
Other Equity Adjustments		 - - - 0.00 -3.50 -1.56 -3.69
Noncontrolling Interest		 - - - - 0.00 0.49 0.51

Quarterly Balance Sheets for Coeptis Therapeutics

This table presents Coeptis Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 7.16 4.67 3.89 4.20 8.96 13 12 14 20
Total Current Assets		 3.80 1.62 1.38 1.99 1.36 4.65 3.69 5.99 5.91
Cash & Equivalents		 3.24 1.41 1.03 1.56 1.14 4.27 2.00 4.91 5.21
Short-Term Investments		 - - - - - - 0.99 0.42 0.05
Note & Lease Receivable		 0.35 0.00 0.11 0.19 0.00 - - 0.00 0.02
Prepaid Expenses		 0.20 0.21 0.24 0.24 0.23 0.38 0.68 0.57 0.63
Plant, Property, & Equipment, net		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Total Noncurrent Assets		 3.35 3.04 2.50 2.20 7.58 8.79 8.49 8.18 14
Intangible Assets		 3.05 2.80 - - - 0.50 0.45 0.41 0.32
Other Noncurrent Operating Assets		 0.29 0.23 2.50 2.20 7.58 8.30 8.03 7.77 14
Total Liabilities & Shareholders' Equity		 7.16 4.67 3.89 4.20 8.96 13 12 14 20
Total Liabilities		 5.20 2.78 5.03 4.51 3.97 5.99 5.11 3.26 2.21
Total Current Liabilities		 3.04 2.23 4.30 3.63 3.44 5.65 4.48 2.71 1.82
Short-Term Debt		 2.20 1.18 2.19 1.55 1.55 1.84 1.14 0.10 0.10
Accounts Payable		 0.40 0.48 1.37 1.28 1.13 1.12 1.03 0.78 1.01
Accrued Expenses		 0.43 0.57 0.72 0.77 0.74 0.60 0.42 0.21 0.06
Current Deferred Revenue		 - - - - - 1.19 1.63 1.46 0.49
Other Current Liabilities		 0.02 0.01 0.03 0.02 0.01 0.90 0.26 0.15 0.16
Total Noncurrent Liabilities		 2.15 0.54 0.73 0.88 0.53 0.34 0.64 0.56 0.39
Long-Term Debt		 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
Other Noncurrent Operating Liabilities		 2.00 0.39 0.58 0.73 0.38 0.19 0.49 0.41 0.24
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1.96 1.89 -1.14 -0.31 4.98 7.46 7.08 11 18
Total Preferred & Common Equity		 1.96 1.89 -1.14 -0.44 4.82 6.48 6.10 10 17
Preferred Stock		 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1.96 1.89 -1.14 -0.44 4.82 6.48 6.10 10 17
Common Stock		 79 88 95 101 102 108 112 121 135
Retained Earnings		 -77 -84 -90 -93 -95 -102 -106 -108 -114
Other Equity Adjustments		 - -2.50 -5.50 -7.55 -2.10 -0.25 0.23 -2.10 -3.65
Noncontrolling Interest		 - - - 0.13 0.16 0.98 0.98 0.55 0.40

Annual Metrics And Ratios for Coeptis Therapeutics

This table displays calculated financial ratios and metrics derived from Coeptis Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 9,656,250.00 9,375,000.00 5,116,414.00 102,324,108.00 41,118,593.00 5,340,111.00
DEI Adjusted Shares Outstanding		 0.00 482,813.00 468,750.00 255,821.00 5,116,205.00 2,055,930.00 5,340,111.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -35.79 -28.69 -146.88 -4.16 -5.19 -2.23
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -773,444.32% 20.06% -138.59% 38.95% 53.31% -4.52%
EBIT Growth		 0.00% -773,444.32% 17.47% -138.13% 37.70% 49.67% -8.81%
NOPAT Growth		 0.00% -2,963.12% -20,425.99% -143.46% 37.15% 53.22% -29.73%
Net Income Growth		 0.00% -773,390.42% 22.17% -179.38% 43.40% 48.85% -12.87%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 48.85% 49.46%
Operating Cash Flow Growth		 0.00% -6,385.15% -3,780.41% 13.67% -86.79% 8.15% -29.38%
Free Cash Flow Firm Growth		 0.00% 0.00% -260.59% 39.52% 42.53% 12.54% -10.54%
Invested Capital Growth		 0.00% -13,746.49% 118.50% -37.19% -82.35% 894.45% 70.52%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 172.07%
EBITDA Q/Q Growth		 0.00% 0.00% -1,544.21% 46.74% -4.83% 7.04% 13.84%
EBIT Q/Q Growth		 0.00% 0.00% -1,597.46% 45.12% -4.76% 5.67% 12.12%
NOPAT Q/Q Growth		 0.00% 0.00% -2,919.64% 23.58% -1.26% 10.69% 1.32%
Net Income Q/Q Growth		 0.00% 0.00% -1,514.02% 41.77% -3.97% 6.40% 10.16%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 6.40% 49.73%
Operating Cash Flow Q/Q Growth		 0.00% -6,673.71% -926.63% 46.13% -13.24% 3.72% -3.01%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 32.33% 39.03% 3.29% -30.25%
Invested Capital Q/Q Growth		 0.00% 0.00% 169.02% 160.27% -73.99% -15.80% 36.51%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 86.75%
EBITDA Margin		 0.00% 0.00% -18,419.64% 0.00% 0.00% 0.00% -720.41%
Operating Margin		 0.00% 0.00% -18,727.91% 0.00% 0.00% 0.00% -956.94%
EBIT Margin		 0.00% 0.00% -19,016.19% 0.00% 0.00% 0.00% -850.14%
Profit (Net Income) Margin		 0.00% 0.00% -17,932.37% 0.00% 0.00% 0.00% -900.72%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 99.99% 94.30% 110.64% 100.51% 102.14% 105.95%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -144.48%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -25.64%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.57%
Return on Equity (ROE)		 -14.24% -64.27% -47.94% -1,104.48% -807.49% -464.73% -136.90%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -872.41% -648.14% -820.70% -437.20% -196.61%
Operating Return on Assets (OROA)		 0.00% 0.00% -34.17% 0.00% 0.00% 0.00% -92.47%
Return on Assets (ROA)		 0.00% 0.00% -32.22% 0.00% 0.00% 0.00% -97.97%
Return on Common Equity (ROCE)		 -14.24% 26.27% 16.79% -1,104.48% -807.49% -416.57% -129.34%
Return on Equity Simple (ROE_SIMPLE)		 -14.24% 78.56% -572.16% -843.73% -2,612.71% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.00 -0.05 -9.83 -24 -15 -7.04 -9.13
NOPAT Margin		 0.00% 0.00% -13,109.54% 0.00% 0.00% 0.00% -669.86%
Net Nonoperating Expense Percent (NNEP)		 0.44% -45.05% -9.68% 28,369.13% -582.81% 1,666.15% -118.84%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -775.87% -135.22% -63.77%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.25%
SG&A Expenses to Revenue		 0.00% 0.00% 18,824.02% 0.00% 0.00% 0.00% 655.89%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.70%
Operating Expenses to Revenue		 0.00% 0.00% 18,827.91% 0.00% 0.00% 0.00% 1,043.69%
Earnings before Interest and Taxes (EBIT)		 -0.00 -17 -14 -34 -21 -11 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.00 -17 -14 -33 -20 -9.40 -9.82
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 4,779.20 0.00 39.88 1.76 32.85 3.34 5.61
Price to Tangible Book Value (P/TBV)		 4,779.20 0.00 39.88 1.76 32.85 3.98 5.76
Price to Revenue (P/Rev)		 0.00 0.00 1,250.00 0.00 0.00 0.00 55.83
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 447.78 0.00 22.57 2.27 56.18 2.70 8.85
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 1,275.17 0.00 0.00 0.00 51.72
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 4.23 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 9.73 0.00 1.73 0.45 1.38 0.35 0.02
Long-Term Debt to Equity		 0.00 0.00 0.70 0.03 0.18 0.04 0.01
Financial Leverage		 9.69 -1.42 -1.33 0.01 -0.41 0.10 -0.30
Leverage Ratio		 10.93 1.43 1.49 2.16 2.37 2.88 1.40
Compound Leverage Factor		 10.93 1.43 1.40 2.39 2.38 2.94 1.48
Debt to Total Capital		 90.68% 0.00% 63.37% 30.99% 58.02% 25.70% 1.75%
Short-Term Debt to Total Capital		 90.68% 0.00% 37.66% 28.67% 50.28% 22.82% 0.70%
Long-Term Debt to Total Capital		 0.00% 0.00% 25.71% 2.32% 7.74% 2.88% 1.05%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 140.92% 0.00% 0.00% 0.00% 9.32% 3.54%
Common Equity to Total Capital		 9.32% -40.92% 36.63% 69.01% 41.98% 64.98% 94.72%
Debt to EBITDA		 -68.33 0.00 -0.29 -0.06 -0.06 -0.14 -0.03
Net Debt to EBITDA		 -68.10 0.00 -0.14 0.05 0.02 -0.09 0.62
Long-Term Debt to EBITDA		 0.00 0.00 -0.12 0.00 -0.01 -0.02 -0.02
Debt to NOPAT		 -97.61 0.00 -0.41 -0.08 -0.07 -0.19 -0.03
Net Debt to NOPAT		 -97.29 0.00 -0.19 0.07 0.02 -0.11 0.67
Long-Term Debt to NOPAT		 0.00 0.00 -0.17 -0.01 -0.01 -0.02 -0.02
Altman Z-Score		 287.53 1.44 -0.01 -24.22 -38.09 -18.47 10.49
Noncontrolling Interest Sharing Ratio		 0.00% 140.88% 135.01% 0.00% 0.00% 10.36% 5.53%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 191.80 0.79 1.81 0.59 0.23 4.16
Quick Ratio		 0.00 181.44 0.79 1.75 0.50 0.12 3.60
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 23 -37 -22 -13 -11 -12
Operating Cash Flow to CapEx		 0.00% 0.00% -256.54% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -197.58 -6.19 -119.34 -24.31 -19.34
Operating Cash Flow to Interest Expense		 0.00 0.00 -23.99 -1.07 -67.23 -14.38 -13.39
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -33.34 -1.07 -67.23 -14.38 -13.39
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.11
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 134.07
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.17
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 2,180.92
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 -2,180.92
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.17 -23 4.24 2.66 0.47 4.67 7.97
Invested Capital Turnover		 0.00 0.00 -0.01 0.00 0.00 0.00 0.22
Increase / (Decrease) in Invested Capital		 0.00 -23 27 -1.58 -2.19 4.20 3.30
Enterprise Value (EV)		 75 97 96 6.04 26 13 71
Market Capitalization		 75 98 94 7.83 27 11 76
Book Value per Share		 $0.01 ($2.28) $0.25 $0.87 $0.02 $0.08 $2.54
Tangible Book Value per Share		 $0.01 ($2.28) $0.25 $0.87 $0.02 $0.07 $2.47
Total Capital		 0.17 54 6.42 6.45 1.94 5.21 14
Total Debt		 0.15 0.00 4.07 2.00 1.13 1.34 0.25
Total Long-Term Debt		 0.00 0.00 1.65 0.15 0.15 0.15 0.15
Net Debt		 0.15 -77 1.89 -1.79 -0.34 0.80 -6.10
Capital Expenditures (CapEx)		 0.00 0.00 1.75 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.00 0.05 -0.35 -0.17 -1.73 -2.81 -0.67
Debt-free Net Working Capital (DFNWC)		 -0.00 0.95 1.83 3.62 -0.26 -2.27 5.68
Net Working Capital (NWC)		 -0.16 0.95 -0.59 1.77 -1.24 -3.46 5.58
Net Nonoperating Expense (NNE)		 0.00 17 3.62 14 6.22 3.84 3.15
Net Nonoperating Obligations (NNO)		 0.15 -77 1.89 -1.79 -0.34 0.80 -6.10
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.45 1.00 1.04 1.25 1.77
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -463.92% 0.00% 0.00% 0.00% -49.07%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 2,442.15% 0.00% 0.00% 0.00% 416.86%
Net Working Capital to Revenue		 0.00% 0.00% -780.51% 0.00% 0.00% 0.00% 409.53%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $1.62 $0.00 $0.00 ($5.65) ($2.81)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 7.50M 0.00 0.00 1.92M 4.23M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($5.65) ($2.81)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 1.88M 0.00 0.00 1.92M 4.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 1.88M 0.00 0.00 3.36M 6.22M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.00 -0.05 -9.83 -24 -15 -7.04 -9.13
Normalized NOPAT Margin		 0.00% 0.00% -13,109.54% 0.00% 0.00% 0.00% -669.86%
Pre Tax Income Margin		 0.00% 0.00% -17,932.37% 0.00% 0.00% 0.00% -900.72%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -76.21 -9.40 -196.49 -23.04 -18.04
NOPAT to Interest Expense		 0.00 0.00 -52.54 -6.63 -139.70 -15.22 -14.21
EBIT Less CapEx to Interest Expense		 0.00 0.00 -85.57 -9.40 -196.49 -23.04 -18.04
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -61.89 -6.63 -139.70 -15.22 -14.21
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -3,951.75% -1.88% -1.84% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Coeptis Therapeutics

This table displays calculated financial ratios and metrics derived from Coeptis Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 50,282,072.00 102,324,108.00 72,179,834.00 74,237,186.00 39,718,593.00 41,118,593.00 3,364,939.00 3,513,838.00 4,820,317.00 5,340,111.00 6,223,221.00
DEI Adjusted Shares Outstanding		 2,514,104.00 5,116,205.00 3,608,992.00 3,711,859.00 1,985,930.00 2,055,930.00 3,364,939.00 3,513,838.00 4,820,317.00 5,340,111.00 6,223,221.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.53 -0.73 -0.83 -0.82 -1.84 -0.48 -1.04 -1.46 -1.20 1.10 -0.66
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 80.95%
EBITDA Growth		 -12.07% -37.83% 68.84% 6.24% 75.21% 20.41% -23.11% -30.98% -64.85% 70.12% -25.07%
EBIT Growth		 -12.07% -34.58% 64.66% 6.03% 71.91% 17.11% -19.59% -43.70% -59.51% 63.39% -19.21%
NOPAT Growth		 -41.89% -8.61% 55.31% 23.25% 72.89% 35.76% -38.82% -59.87% -15.65% 8.04% 3.51%
Net Income Growth		 -12.42% -27.61% 62.28% 5.22% 71.20% 19.81% -125.81% -42.80% -58.50% 46.11% -17.12%
EPS Growth		 0.00% 0.00% 62.28% 0.00% 0.00% 19.81% -1,275.00% 0.00% 0.00% 370.59% 40.91%
Operating Cash Flow Growth		 -89.54% -99.89% -12.94% 25.50% 3.36% 15.19% -24.38% -69.05% -13.72% -17.50% 25.67%
Free Cash Flow Firm Growth		 -109.07% 72.36% 83.77% 89.83% 55.40% -3,385.71% -433.08% -1,057.09% 61.43% 18.00% -28.86%
Invested Capital Growth		 140.90% -82.35% -77.34% -115.13% 207.19% 894.45% 2,992.57% 3,440.35% 5.18% 70.52% 142.43%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 219.18% 18.32% 263.06% -86.80%
EBITDA Q/Q Growth		 -107.93% 42.36% 31.42% -14.08% 45.03% -85.06% -6.08% -21.37% 30.81% 66.45% -343.99%
EBIT Q/Q Growth		 -100.34% 40.90% 25.15% -6.01% 40.12% -74.45% -7.99% -27.39% 33.53% 59.97% -251.68%
NOPAT Q/Q Growth		 -114.42% 57.40% 13.18% 3.23% 24.27% -0.95% -87.63% -11.44% 45.21% 19.73% -96.89%
Net Income Q/Q Growth		 -98.29% 40.86% 20.08% -1.13% 39.75% -64.68% -125.03% -26.71% 33.12% 44.01% -389.09%
EPS Q/Q Growth		 -60.00% 40.86% 20.08% 0.00% 0.00% 0.00% -115.69% 0.00% 0.00% 0.00% -147.10%
Operating Cash Flow Q/Q Growth		 -2.92% 13.51% -12.32% 25.48% -33.50% 24.10% -64.71% -1.29% 10.20% 21.57% -4.21%
Free Cash Flow Firm Q/Q Growth		 -58.72% 98.60% -798.70% 48.92% -596.28% -9.05% -37.44% -10.88% 76.79% -131.84% -116.00%
Invested Capital Q/Q Growth		 69.51% -73.99% -64.32% -196.17% 3,542.11% -15.80% 10.95% 3.88% 8.39% 36.51% 57.73%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 28.18% 77.50% 80.98% 94.76% 60.31%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,682.82% -1,780.69% -1,041.27% -96.21% -3,236.72%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,452.56% -2,252.94% -1,043.22% -230.64% -3,440.81%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,327.24% -2,126.16% -1,194.47% -131.71% -3,509.64%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,779.46% -2,159.94% -1,220.84% -188.26% -6,976.75%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 198.12% 100.00% 100.00% 100.00% 197.41%
Interest Burden Percent		 100.31% 100.37% 107.16% 102.22% 102.86% 97.10% 102.13% 101.59% 102.21% 142.94% 100.70%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -106.14% -159.14% -64.27% -34.82% -383.71%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 705.01% -7.86% -12.65% -26.09% -241.14%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -108.26% 1.79% 3.59% 7.71% 70.21%
Return on Equity (ROE)		 -133.70% -807.49% 11,086.70% -1,956.25% -338.06% -464.73% -214.40% -157.34% -60.67% -27.12% -313.50%
Cash Return on Invested Capital (CROIC)		 -1,166.98% -820.70% -2,632.34% 0.00% -316.05% -437.20% -480.19% -270.46% -167.58% -196.61% -184.94%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -38.62% -68.38% -51.73% -14.33% -298.58%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -78.14% -69.47% -52.87% -20.48% -593.55%
Return on Common Equity (ROCE)		 11.67% -807.49% 11,086.70% -1,799.19% -330.30% -416.57% -181.02% -131.39% -57.97% -25.62% -296.15%
Return on Equity Simple (ROE_SIMPLE)		 -1,080.58% 0.00% 1,429.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.53 -2.36 -2.05 -1.98 -1.50 -1.51 -2.84 -3.16 -1.73 -1.39 -2.74
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,516.79% -1,577.06% -730.25% -161.45% -2,408.57%
Net Nonoperating Expense Percent (NNEP)		 -4.94% -131.07% 159.10% -283.04% 137.37% 650.19% -811.15% -151.28% -51.61% -8.73% -142.57%
Return On Investment Capital (ROIC_SIMPLE)		 - -121.52% -170.92% -142.03% -22.42% -29.08% -30.04% -37.80% -15.53% -9.72% -15.37%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 71.82% 22.50% 19.02% 5.24% 39.69%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,126.73% 1,745.37% 532.13% 183.21% 1,458.06%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 137.83% 144.66% 247.34% 36.30% 207.02%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,480.74% 2,330.43% 1,124.20% 325.41% 3,501.12%
Earnings before Interest and Taxes (EBIT)		 -6.33 -3.74 -2.80 -2.97 -1.78 -3.10 -3.35 -4.27 -2.84 -1.14 -3.99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.05 -3.49 -2.39 -2.73 -1.50 -2.78 -2.94 -3.57 -2.47 -0.83 -3.68
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 15.41 32.85 0.00 0.00 1.48 3.34 4.87 4.50 8.12 5.61 4.07
Price to Tangible Book Value (P/TBV)		 0.00 32.85 0.00 0.00 1.48 3.98 5.27 4.86 8.45 5.76 4.14
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 501.47 103.99 167.99 55.83 49.38
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 16.10 56.18 71.84 0.00 1.42 2.70 5.83 4.96 13.64 8.85 5.19
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 480.88 101.30 158.95 51.72 46.12
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.70 1.38 -2.05 -5.50 0.34 0.35 0.27 0.18 0.02 0.02 0.01
Long-Term Debt to Equity		 0.08 0.18 -0.13 -0.48 0.03 0.04 0.02 0.02 0.01 0.01 0.01
Financial Leverage		 -1.09 -0.41 -4.08 -0.45 0.07 0.10 -0.15 -0.23 -0.28 -0.30 -0.29
Leverage Ratio		 1.24 2.37 -33.43 6.88 1.98 2.88 2.74 2.42 1.46 1.40 1.33
Compound Leverage Factor		 1.24 2.38 -35.83 7.03 2.04 2.80 2.80 2.46 1.49 2.00 1.34
Debt to Total Capital		 41.18% 58.02% 195.30% 122.24% 25.48% 25.70% 21.05% 15.43% 2.24% 1.75% 1.40%
Short-Term Debt to Total Capital		 36.51% 50.28% 182.77% 111.48% 23.24% 22.82% 19.46% 13.64% 0.90% 0.70% 0.56%
Long-Term Debt to Total Capital		 4.66% 7.74% 12.53% 10.76% 2.24% 2.88% 1.59% 1.79% 1.34% 1.05% 0.84%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 9.51% 2.36% 9.32% 10.41% 11.76% 4.94% 3.54% 2.25%
Common Equity to Total Capital		 58.82% 41.98% -95.30% -31.75% 72.16% 64.98% 68.54% 72.81% 92.83% 94.72% 96.34%
Debt to EBITDA		 -0.07 -0.06 -0.16 -0.12 -0.17 -0.14 -0.20 -0.12 -0.02 -0.03 -0.02
Net Debt to EBITDA		 0.00 0.02 -0.09 -0.01 -0.06 -0.09 0.23 0.16 0.45 0.62 0.47
Long-Term Debt to EBITDA		 -0.01 -0.01 -0.01 -0.01 -0.01 -0.02 -0.02 -0.01 -0.01 -0.02 -0.01
Debt to NOPAT		 -0.09 -0.07 -0.19 -0.14 -0.22 -0.19 -0.25 -0.14 -0.03 -0.03 -0.03
Net Debt to NOPAT		 0.01 0.02 -0.10 -0.01 -0.07 -0.11 0.29 0.19 0.55 0.67 0.56
Long-Term Debt to NOPAT		 -0.01 -0.01 -0.01 -0.01 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02
Altman Z-Score		 -23.39 -25.51 -34.48 -32.52 -14.74 -15.68 -8.33 -10.16 4.42 12.63 10.57
Noncontrolling Interest Sharing Ratio		 108.73% 0.00% 0.00% 8.03% 2.29% 10.36% 15.57% 16.50% 4.46% 5.53% 5.54%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.73 0.59 0.32 0.55 0.40 0.23 0.82 0.83 2.21 4.16 3.25
Quick Ratio		 0.63 0.50 0.26 0.48 0.33 0.12 0.76 0.67 2.00 3.60 2.90
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -0.16 -1.47 -0.75 -5.24 -5.72 -7.86 -8.71 -2.02 -4.69 -10
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -593.62 -11.86 -7.35 -11.40 -102.93 -39.47 -109.89 -128.50 -32.29 -10.64 -1,925.73
Operating Cash Flow to Interest Expense		 -98.91 -122.45 -9.49 -21.46 -37.16 -9.92 -33.10 -35.36 -34.38 -3.83 -334.58
Operating Cash Flow Less CapEx to Interest Expense		 -98.91 -122.45 -9.49 -21.46 -37.16 -9.92 -33.10 -35.36 -34.38 -3.83 -334.58
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.04 0.11 0.09
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 5.87 25.04 48.42 134.07 141.11
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.08 0.14 0.17 0.17
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 10,049.52 4,667.89 2,583.01 2,180.92 2,153.96
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 -10,049.52 -4,667.89 -2,583.01 -2,180.92 -2,153.96
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1.81 0.47 0.17 -0.16 5.55 4.67 5.18 5.38 5.84 7.97 13
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.10 0.09 0.22 0.16
Increase / (Decrease) in Invested Capital		 6.22 -2.19 -0.57 -1.23 3.74 4.20 5.02 5.55 0.29 3.30 7.38
Enterprise Value (EV)		 29 26 12 11 7.87 13 30 27 80 71 65
Market Capitalization		 29 27 11 11 7.15 11 32 27 84 76 70
Book Value per Share		 $0.08 $0.02 ($0.03) ($0.01) $0.12 $0.08 $1.93 $1.26 $2.15 $2.54 $2.76
Tangible Book Value per Share		 ($0.04) $0.02 ($0.03) ($0.01) $0.12 $0.07 $1.78 $1.17 $2.07 $2.47 $2.71
Total Capital		 3.22 1.94 1.20 1.39 6.69 5.21 9.45 8.37 11 14 18
Total Debt		 1.33 1.13 2.34 1.70 1.70 1.34 1.99 1.29 0.25 0.25 0.25
Total Long-Term Debt		 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
Net Debt		 -0.09 -0.34 1.31 0.15 0.57 0.80 -2.28 -1.70 -5.08 -6.10 -5.01
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.85 -1.73 -1.76 -1.64 -1.66 -2.81 -3.43 -2.63 -1.94 -0.67 -1.07
Debt-free Net Working Capital (DFNWC)		 0.56 -0.26 -0.73 -0.08 -0.52 -2.27 0.84 0.36 3.39 5.68 4.19
Net Working Capital (NWC)		 -0.61 -1.24 -2.92 -1.63 -2.08 -3.46 -1.00 -0.78 3.29 5.58 4.09
Net Nonoperating Expense (NNE)		 0.82 1.40 0.96 1.06 0.33 1.50 3.94 1.17 1.16 0.23 5.20
Net Nonoperating Obligations (NNO)		 -0.09 -0.34 1.31 0.15 0.57 0.80 -2.28 -1.70 -5.08 -6.10 -5.01
Total Depreciation and Amortization (D&A)		 0.28 0.25 0.41 0.24 0.28 0.33 0.41 0.69 0.36 0.31 0.31
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,455.80% -996.22% -388.16% -49.07% -75.74%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,332.96% 137.25% 675.75% 416.86% 296.39%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,592.32% -296.06% 655.79% 409.53% 289.32%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($58.40) $0.00 ($1.60) ($1.00) ($10.20) ($1.11) $0.00 $0.00 $1.38 ($0.65)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 64.23K 0.00 1.88M 1.99M 96.23K 3.07M 4.82M 5.34M 4.23M 6.03M
Adjusted Diluted Earnings per Share		 $0.00 ($58.40) $0.00 ($1.60) ($1.00) ($10.20) ($1.11) $0.00 $0.00 $1.38 ($0.65)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 64.23K 0.00 1.88M 1.99M 96.23K 3.07M 4.82M 5.34M 4.23M 6.03M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($58.40) $0.00 $0.00 $0.00 ($10.20) $0.00 $0.00 $0.00 $1.38 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.80M 0.00 1.99M 2.06M 168.25K 3.51M 4.82M 5.34M 6.22M 51.43M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.45 -2.36 -2.05 -1.98 -1.50 -1.51 -2.84 -3.16 -1.73 -1.39 -2.74
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,516.79% -1,577.06% -730.25% -161.45% -2,408.57%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,440.95% -2,159.94% -1,220.84% -188.26% -3,534.20%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -319.73 -270.51 -13.97 -44.95 -34.91 -21.42 -46.85 -62.94 -45.30 -2.58 -759.55
NOPAT to Interest Expense		 -279.34 -170.34 -10.20 -29.97 -29.44 -10.45 -39.72 -46.69 -27.69 -3.16 -521.26
EBIT Less CapEx to Interest Expense		 -319.73 -270.51 -13.97 -44.95 -34.91 -21.42 -46.85 -62.94 -45.30 -2.58 -759.55
NOPAT Less CapEx to Interest Expense		 -279.34 -170.34 -10.20 -29.97 -29.44 -10.45 -39.72 -46.69 -27.69 -3.16 -521.26
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Coeptis Therapeutics’ latest quarter shows a company still struggling to generate consistent operating profits, but with a relatively strong cash position and a balance sheet that improved materially versus prior periods. Revenue remains small and uneven, while operating losses continue to outweigh gross profit. The bigger picture is that the company has relied heavily on financing and share issuance to support operations.

  • Cash and equivalents rose to $5.2 million at the end of Q1 2026, up from $4.9 million in Q3 2025 and well above Q1 2025 levels.
  • Total current assets increased to $5.9 million, giving the company a more liquid near-term position.
  • Net change in cash was only a modest $(463,114) in Q1 2026, a significant improvement from the much larger operating cash burn seen in earlier periods.
  • The company generated some investment and financing cash inflows in Q1 2026, including $591,519 from sale/maturity of investments and $704,254 in other financing activities.
  • Total liabilities fell sharply to $2.2 million in Q1 2026 from $3.3 million in Q3 2025, suggesting a cleaner balance sheet.
  • Gross margin remained positive in Q1 2026, with $68,615 in gross profit on $113,771 of revenue.
  • Deferred revenue was $485,684 in Q1 2026, which could indicate some future revenue recognition if the business can execute.
  • Long-term debt stayed low at $150,000, while short-term debt was only $100,000 in Q1 2026.
  • Q1 2026 revenue was only $113,771, down sharply from $862,049 in Q4 2025, showing very limited top-line scale.
  • The company reported a Q1 2026 net loss of $(4.0 million) and an operating loss of $(3.9 million), highlighting that expenses still far exceed gross profit.
  • Operating cash flow was negative $(1.8 million) in Q1 2026, so the business is still burning cash from core operations.
  • Q1 2026 earnings per share were $(0.65), and prior quarters also showed persistent losses, indicating no clear profitability trend yet.
  • The company has repeatedly relied on equity issuance for cash, which can be dilutive to existing shareholders; this was especially evident in 2024 and 2025.
  • Shares outstanding have been volatile and generally much higher than in earlier periods, reflecting ongoing dilution and capital raises.

Overall: Coeptis Therapeutics appears better capitalized than it was a year ago, but the core business remains unprofitable and cash-generative performance is still negative. Investors should watch whether revenue can scale meaningfully and whether operating losses can narrow without additional dilution.

06/19/26 04:35 AM ETAI Generated. May Contain Errors.

Coeptis Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Coeptis Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Coeptis Therapeutics' net income appears to be on an upward trend, with a most recent value of -$12.28 million in 2025, rising from -$2.23 thousand in 2019. The previous period was -$10.88 million in 2024. Find out what analysts predict for Coeptis Therapeutics in the coming months.

Coeptis Therapeutics' total operating income in 2025 was -$13.04 million, based on the following breakdown:
  • Total Gross Profit: $1.18 million
  • Total Operating Expenses: $14.23 million

Over the last 6 years, Coeptis Therapeutics' total revenue changed from $0.00 in 2019 to $1.36 million in 2025, a change of 136,304,500.0%.

Coeptis Therapeutics' total liabilities were at $2.09 million at the end of 2025, a 58.6% decrease from 2024, and a 1,238.3% increase since 2019.

In the past 6 years, Coeptis Therapeutics' cash and equivalents has ranged from $505.00 in 2019 to $5.67 million in 2025, and is currently $5.67 million as of their latest financial filing in 2025.

Over the last 6 years, Coeptis Therapeutics' book value per share changed from 0.01 in 2019 to 2.54 in 2025, a change of 27,807.7%.


Related Companies

Financial statements for NASDAQ:ZSQR last updated on 6/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...
Behind the Markets | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
A huge SpaceX error just led one stock to 3X move!
SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....
InvestPub | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel